.Pharmacolibrary.Drugs.ATC.J.J07BK03 .Pharmacolibrary.Drugs.ATC.J.J07BK03| name: | ZosterPurifiedAntigen | |
| ATC code: | J07BK03 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Zoster, purified antigen (subunit vaccine), is an inactivated recombinant vaccine based on herpes zoster virus glycoprotein E (gE) combined with an adjuvant system. It is used to prevent shingles (herpes zoster) and its complications, particularly in adults aged 50 years and older. A well-known example is Shingrix, which is approved and widely used today for immunization against shingles.
No published pharmacokinetic parameters are available in the literature for zoster, purified antigen vaccine. As a non-replicating recombinant protein administered intramuscularly, systemic pharmacokinetics are not typically measurable in terms of absorption, distribution, metabolism, and excretion as applied to small-molecule drugs. Any pharmacokinetic properties would be theoretical or based on other protein vaccines with similar administration routes.